N-Myc Antibody 9405S from Cell Signaling Technology

Product Specs
ItemN-Myc Antibody
CompanyCell Signaling Technology
Price $306.00 Inquire
Catalog Number9405S
Quantity100 µl
ApplicationsW
ReactivityH
TargetN-Myc
HostRabbit
NCBI Gene AliasesMODED, MYCNsORF, MYCNsPEP, N-myc, NMYC, ODED, bHLHe37
NCBI Full Gene NameMYCN proto-oncogene, bHLH transcription factor
ClonalityPolyclonal
Research AreaApoptosis
Molecular Weight62

Questions and Answers

Can this antibody be used to study N-Myc expression in neuroblastoma cells?

Yes, the N-Myc antibody has been utilized in various studies to assess N-Myc expression in neuroblastoma cells. For instance, it was employed in the study by Clark et al. () to evaluate the effects of pralatrexate on MYCN expression in MYCN-amplified neuroblastoma cells.

What is the specificity of this antibody regarding Myc family proteins?

The N-Myc antibody specifically detects endogenous levels of human N-Myc and transfected levels of mouse N-Myc without cross-reacting with other Myc family members, making it suitable for studies focused on N-Myc alone.

How has this antibody been applied in research related to apoptosis in neuroblastoma?

The N-Myc antibody has been used in immunoblotting to confirm apoptosis in neuroblastoma cells, as demonstrated in studies where N-Myc expression was linked to cell cycle arrest and apoptosis induction ().

Is there evidence of this antibody being used in combination therapies for neuroblastoma?

Yes, the N-Myc antibody has been referenced in studies exploring combination therapies for neuroblastoma, such as in the context of ALK inhibitors and p53 activators, where its expression was monitored to assess treatment efficacy ().

Cell Signaling Technology

3 Trask Lane

Danvers, Massachusetts 01923

United States

Phone: 877-616-CELL
Phone: 978-867-2388
Fax: 866-432-6112
Fax: 978-867-2488

Company Profile

Website: http://www.cellsignal.com/

Website: Technical Support

(1) Neuronal differentiation of neuroblastoma cell lines for neurological disease modelingiScienceJuly 17, 2026Claudia Pommerenke, Vivien Hauer, Sonja Eberth, Lisa Werr, Hannah Kallnischkies, Ulfert Rand, Stefan Nagel, Christoph Bartenhagen, Wilhelm Gerhard Dirks, Matthias Fischer, et al.RESOURCE,SOURCE,IDENTIFIER Antibodies,Antibodies,Antibodies ,, "Anti-N-MYC, rabbit polyclonal",Cell Signaling,Cat# 9405; RRID: AB_10692664 "Anti-GAPDH, mouse monoclonal",Abcam,Cat# ab8245; RRID: AB_2107448 "Anti-Ki67,

(2) Core transcriptional regulatory circuit-regulated IGF2BP3 stabilizes E2F2 mRNA via m6A modification in neuroblastomaCarcinogenesisSeptember 4, 2025Pengcheng Yang, Jianwei Wang, Ziheng Wu, Ran Zhuo, Yanling Chen, Gen Li, Yanfang Tao, Xiaolu Li, Fang Fang, Di Wu, et al.Supplementary Table S1. 2.2. Antibodies The primary antibodies used in this study were as follows: MYCN (9405S, CST), E2F2 (ab235837, Abcam), IGF2BP3 (14642-1-AP, Proteintech), Ki-67 (GB111499, Servicebio), cleaved

(3) Kinome Reprogramming of G2/M Kinases and Repression of MYCN Contribute to Superior Efficacy of Lorlatinib in ALK-Driven NeuroblastomaMolecular Cancer TherapeuticsSeptember 2, 2025Smita Matkar, Michael P. East, Timothy J. Stuhlmiller, Gabriela M. Witek, Alvin Farrel, Steven Pastor, Denis O. Okumu, Anne Kennedy, Joshua R. Kalna, Esther R. Berko, et al.RRID: AB_330744, Cat. # 4695), FER (RRID: AB_2278286, Cat. # 4268), and MYCN (RRID: AB_10692664, Cat. # 9405) which were purchased from Cell Signaling Technology and β-actin antibody which was purchased from Santa Cruz Biotechnology

(4) Identification of MUC1-C Dependence in Drug-Resistant Advanced Prostate Cancer Uncovers a Target for Antibody-Drug Conjugate TherapyJCI InsightJuly 22, 2025Keisuke Shigeta, Tatsuaki Daimon, Hiroshi Hongo, Sheng-Yu Ku, Hiroki Ozawa, Naoki Haratake, Atsushi Fushimi, Ayako Nakashoji, Atrayee Bhattacharya, Shinkichi Takamori, et al.dilution; Invitrogen), anti-MYC (9402, 1:1,000 dilution; Cell Signaling Technology [CST]), anti-MYCN (9405, 1:1,000 dilution; CST), anti-BRN2 (12137, 1:1,000 dilution; CST), anti-ASCL1 (GTX129189, 1:1,000 dilution;

(5) Exploring FAM13A-N-Myc interactions to uncover potential targets in MYCN-amplified neuroblastoma: a study of protein interactions and molecular dynamics simulationsBMC CancerMarch 14, 2025Hongli Yin, Tianyi Liu, Di Wu, Xiaolu Li, Gen Li, Weiwei Song, Xiaodong Wang, Shan Xin, Yisu Liu, Jian Pan(Millipore, USA). The antibodies used were specific for FAM13A (55401-1-AP, Proteintech, USA), N-Myc (9405 S, Cell Signaling Technology, USA), Cleaved caspase-3 (9661 S, Cell Signaling Technology, USA), PARP

(6) Kinome Reprogramming of G2/M Kinases and Repression of MYCN Contribute to Superior Efficacy of Lorlatinib in ALK-Driven NeuroblastomaMol Cancer TherFebruary 5, 2025Smita Matkar, Michael P. East, Timothy J. Stuhlmiller, Gabriela M. Witek, Alvin Farrel, Steven Pastor, Denis O. Okumu, Anne Kennedy, Joshua R. Kalna, Esther R. Berko, et al.RRID: AB_330744, Cat. # 4695), FER (RRID: AB_2278286, Cat. # 4268), and MYCN (RRID: AB_10692664, Cat. # 9405) which were purchased from Cell Signaling Technology and β-actin antibody which was purchased from Santa Cruz Biotechnology

(7) Identification and Characterization of Chemotherapy-Resistant High-Risk Neuroblastoma Persister CellsCancer DiscoveryDecember 2, 2024Liron D. Grossmann, Chia-Hui Chen, Yasin Uzun, Anusha Thadi, Adam J. Wolpaw, Kevin Louault, Yael Goldstein, Lea F. Surrey, Daniel Martinez, Matteo Calafatti, et al.(1:5,000; CST, #4967), GAPDH (1:5,000; CST, #2118), c-MYC (1:1,000; CST, #18583), N-MYC (1:5,000; CST, #9405), p65 (1:5,000; CST, #4767), PRRX1 (1:2,000; OriGene TA803116), YAP (1:1,000; CST, #14074), PHOX2B (1:200,

(8) Novel PP2A-Activating Compounds in NeuroblastomaCancers (Basel)November 15, 2024Nazia Nazam, Laura V. Bownes, Janet R. Julson, Colin H. Quinn, Michael H. Erwin, Raoud Marayati, Hooper R. Markert, Sorina Shirley, Jerry E. Stewart, Karina J. Yoon, et al.Antibodies For Western blotting, the following primary antibodies were utilized: rabbit polyclonal anti-MYCN (9405S), anti-MYCN-S62 (13748S) from Cell Signaling (Danvers, MA, USA), rabbit polyclonal anti-CIP2A (ab99518),

(9) MYC phase separation selectively modulates the transcriptomeNature Structural & Molecular BiologyOctober 1, 2024Junjiao Yang, Chan-I Chung, Jessica Koach, Hongjiang Liu, Ambuja Navalkar, Hao He, Zhimin Ma, Qian Zhao, Xiaoyu Yang, Liang He, et al.anti-RNA polymerase II CTD repeat YSPTSPS (phospho S5) antibody,Abcam ab5408,1:200,overnight,4 °C Anti-N-myc antibody,Cell Signaling 9405S,1:100,overnight,4 °C Anti-MED1 antibody (for Kelly cells),Abcam ab64965,1:50,overnight,4 °C Anti-MycN

(10) USP44 Overexpression Drives a MYC-Like Gene Expression Program in Neuroblastoma through Epigenetic ReprogrammingMolecular Cancer ResearchSeptember 4, 2024Thomas L. Ekstrom, Sajjad Hussain, Tibor Bedekovics, Asma Ali, Lucia Paolini, Hina Mahmood, Raya M. Rosok, Jan Koster, Steven A. Johnsen, Paul J. GalardyCell Signaling Technology antibodies: histone H2B (8135), mono-Ub-H2B (5546), RNF20 (9425), histone H3 (4499), and MYCN (9405). The USP44 antibody is from Santa Cruz (#sc-377203). All blots were developed using film and blots

(11) Identification and Characterization of Chemotherapy-Resistant High-Risk Neuroblastoma Persister CellsCancer DiscovJuly 31, 2024Liron D. Grossmann, Chia-Hui Chen, Yasin Uzun, Anusha Thadi, Adam J. Wolpaw, Kevin Louault, Yael Goldstein, Lea F. Surrey, Daniel Martinez, Matteo Calafatti, et al.(1:5,000; CST, #4967), GAPDH (1:5,000; CST, #2118), c-MYC (1:1,000; CST, #18583), N-MYC (1:5,000; CST, #9405), p65 (1:5,000; CST, #4767), PRRX1 (1:2,000; OriGene TA803116), YAP (1:1,000; CST, #14074), PHOX2B (1:200,

(12) USP44 Overexpression Drives a MYC-Like Gene Expression Program in Neuroblastoma through Epigenetic ReprogrammingMol Cancer ResMay 22, 2024Thomas L. Ekstrom, Sajjad Hussain, Tibor Bedekovics, Asma Ali, Lucia Paolini, Hina Mahmood, Raya M. Rosok, Jan Koster, Steven A. Johnsen, Paul J. GalardyCell Signaling Technology antibodies: histone H2B (8135), mono-Ub-H2B (5546), RNF20 (9425), histone H3 (4499), and MYCN (9405). The USP44 antibody is from Santa Cruz (#sc-377203). All blots were developed using film and blots

(13) Epigenetic targeting of PGBD5-dependent DNA damage in SMARCB1-deficient sarcomasbioRxivMay 10, 2024Yaniv Kazansky, Helen S. Mueller, Daniel Cameron, Phillip Demarest, Nadia Zaffaroni, Noemi Arrighetti, Valentina Zuco, Prabhjot S. Mundi, Yasumichi Kuwahara, Romel Somwar, et al.anti-pCHK1 S296 (Cell Signaling Technology, 90178) at 1:250, anti-MYCN (Cell Signaling Technology, 9405) at 1:250, anti-Actin (Cell Signaling Technology, 4970 and 3700) at 1:5,000. Blotted membranes were

(14) DFMO inhibition of neuroblastoma tumorigenesisCancer MedicineMay 1, 2024Divya Gandra, David H. Mulama, David M. Foureau, Kimberly Q. McKinney, Elizabeth Kim, Kaitlyn Smith, Jason Haw, Abhinav Nagulapally, Giselle L. Saulnier Shollerto ODC1 (# ab126590), (Abcam, Cambridge, UK), rabbit monoclonal antibody to LIN28B (#4196), N‐MYC (#9405), and β‐Actin (#4970), (Cell Signaling, Danvers, MA). Goat anti‐rabbit and goat anti‐mouse horseradish

(15) Inhibition of OCT4 binding at the MYCN locus induces neuroblastoma cell death accompanied by downregulation of transcripts with high-open reading frame dominanceFrontiers in OncologyFebruary 8, 2024Kazuma Nakatani, Hiroyuki Kogashi, Takanori Miyamoto, Taiki Setoguchi, Tetsushi Sakuma, Kazuto Kugou, Yoshinori Hasegawa, Takashi Yamamoto, Yoshitaka Hippo, Yusuke Suenagadenatured for 5 min at 95 °C. The primary antibody used in the present study was MYCN (1:100 dilution; #9405, Cell Signaling Technology, Danvers, MA). The Abby measurement was performed using a 12–230 kDa separation

(16) Evaluating the RIST Molecular-Targeted Regimen in a Three-Dimensional Neuroblastoma Spheroid Cell Culture ModelCancers (Basel)March 14, 2023Carina Kaess, Marie Matthes, Jonas Gross, Rebecca Waetzig, Tilman Heise, Selim Corbacioglu, Gunhild Sommer4E-BP1 (Cell Signaling, #9644), phospho-4E-BP1(Ser65, Cell Signaling, #9456), MycN (Cell Signaling, #9405), p70S6 kinase (Cell Signaling, #9202), phospho-p70S6 kinase (Thr389, Cell Signaling, #9234), Src kinase

(17) ONC201 Suppresses Neuroblastoma Growth by Interrupting Mitochondrial Function and Reactivating Nuclear ATRX Expression While Decreasing MYCNInternational journal of molecular sciencesJanuary 13, 2023Wu JC, Huang CC, Wang PW, Chen TY, Hsu WM, Chuang JH, Chuang HC.(199303) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Cleaved caspase 3 (Asp175) and N-Myc (9405S) antibodies were purchased from Cell Signaling Technology (Danvers, MA, USA). ClpX (ab168338), ATRX

(18) EIF4EBP1 is transcriptionally upregulated by MYCN and associates with poor prognosis in neuroblastomaCell Death DiscoveryDecember 1, 2022Kai Voeltzke, Katerina Scharov, Cornelius Maximilian Funk, Alisa Kahler, Daniel Picard, Laura Hauffe, Martin F. Orth, Marc Remke, Irene Esposito, Thomas Kirchner, et al.primary antibodies: 4EBP1 (1:1000; #9644, Cell Signaling Technology, Cambridge, UK), MYCN (1:1,000; #9405, Cell Signaling Technology), GAPDH (1:1000; #2118, Cell Signaling Technology), and β-Actin (1:5,000;

(19) Stanniocalcin 2 drives malignant transformation of human glioblastoma cells by targeting SNAI2 and Matrix MetalloproteinasesCell Death DiscoveryDecember 1, 2022Eun-Jin Yun, Donghwi Kim, Jer-Tsong Hsieh, Seung Tae BaekCell Signaling Technology), anti-Vimentin (Cat#5741, Cell Signaling Technology). Human recombinant STC2 (Cat#9405-SO) was purchased from R&D Systems. LGK974 (S7143), LY3214996 (S8534), Rapamycin (S1039), LY294002 (S1105),

(20) Chromosome 11q loss and MYCN amplification demonstrate synthetic lethality with checkpoint kinase 1 inhibition in neuroblastomaFrontiers in OncologySeptember 27, 2022Kaylee M. Keller, Thomas F. Eleveld, Linda Schild, Kim van den Handel, Marlinde van den Boogaard, Vicky Amo-Addae, Selma Eising, Kimberley Ober, Bianca Koopmans, Leendert Looijenga, et al.Proteins of interest were detected using the following antibodies: anti-N-myc (Cell Signaling, Cat: 9405), anti-CHK1 (Cell Signaling, Cat: 2360), anti-phospho-CHK1 S296 (Cell Signaling, Cat: 2349), anti-WEE1

Be the First to Write a Review!

N-Myc Antibody

N-Myc Antibody from Cell Signaling Technology

Description

Questions and Answers

Cell Signaling Technology

Citations (93)

Reviews

N-Myc Antibody from Cell Signaling Technology

About Biocompare

Advertise with Us

Specialized Search Tools

Site Map